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a b s t r a c t
HIV genomic sequence variability has complicated efforts to generate an effective globally relevant vac-
cine. Regions of the viral genome conserved in sequence and across time may represent the “Achilles’
heel” of HIV. In this study, highly conserved T-cell epitopeswere selected using immunoinformatics tools
combining HLA-A2 supertype binding predictions with relative global conservation. Analysis performed
in 2002 on 10,803HIV-1 sequences, and again in 2009, on 43,822 sequences, yielded 38HLA-A2 epitopes.
These epitopes were experimentally validated for HLA binding and immunogenicity with PBMCs from
HIV-infected patients in Providence, Rhode Island, and/or Bamako, Mali. Thirty-ﬁve (92%) stimulated an
IFN response in PBMCs from at least one subject. Eleven of fourteen peptides (79%) were conﬁrmed as
HLA-A2epitopes inboth locations. Validationof theseHLA-A2epitopes conservedacross time, clades, and
geography supports the hypothesis that such epitopes could provide effective coverage of virus diversity
and would be appropriate for inclusion in a globally relevant HIV vaccine.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
1. Introduction
Thedevelopmentof a safe andefﬁcaciousHIVvaccine isbelieved
to be essential for stopping the AIDS pandemic [1–3]. Two major
factors confounding vaccine design have been the extensive viral
diversity of HIV-1 worldwide and the ongoing evolution and adap-
tation of virus sequences to HLA class I molecules driven by CD8+
cytotoxic T-cell (CTL)-mediated immune pressure [4,5]. In addi-
tion, the insufﬁcient understanding of the complex roles of innate
and adaptive immune responses in natural infection, as well as
the immune correlates of protection, has made developing a vac-
cine capable of responding to these changes difﬁcult. Indeed, the
variability of HIV-1 may in part help explain the failure of recent
HIV-1 candidatevaccines to elicit immune responses that recognize
contemporaneous circulating virus stains. Neither the AIDSVAX
vaccine [6–8], designed to generate antibody responses, nor the
Merck AD5 [9,10], designed to raise T-cell responses, was able to
∗ Corresponding author at: EpiVax, Inc., 146 Clifford Street, Providence, RI 02903,
United States. Tel.: +1 401 272 2123; fax: +1 401 272 7562.
E-mail address: AnnieD@EpiVax.com (A.S. De Groot).
prevent infection or alter disease among high-risk HIV-negative
individuals. It has been suggested that these failures may be due to
the inability of these vaccines to elicit cross-reactive broadly neu-
tralizing antibodies and sufﬁcient breadth and magnitude of T-cell
responses at mucosal portals of entry [11–13]. The RV144 vaccine
trial demonstrated modest success, leading to a 31% lowered rate
of HIV-1 infection in a speciﬁc subset of vaccinees versus placebo
groups [14]. While the correlates of immunity of that trial remain
to be understood, viral diversity is likely to be at least partially
responsible for the limited coverage.
HIV-1-speciﬁc CD4+ T helper cells and CD8+ cytotoxic T cells
have been shown to play a central role in control of the virus fol-
lowing infection [15–21]. CD4+ T helper cells are essential for the
generation of both humoral and cellular responses against the virus
[22,23], while cytotoxic T cells play an important role in the res-
olution of acute viremia and in control of persistent HIV-1 viral
replication [17,24]. Recent longitudinal studies followingﬁrst CD8+
CTL responses to founder virus in early infection have deﬁned a
narrow window of opportunity for the CTL response to control
infection and revealed multiple evolutionary pathways utilized by
the virus during acute infection to retain replicativeﬁtness [25–28].
Moreover, roles for both cytolytic function of CD8+ T cells during
0264-410X © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
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nonproductive infection and noncytolytic functions (e.g., MIP-1,
MIP-1, IFN, TNF, and IL-1) in resolution of peak viremia have
been identiﬁed [29,30]. Therefore, vaccines that stimulate virus-
speciﬁc T-cell responses may  be able to boost humoral immune
responses and may  also delay the progression of HIV-1 to AIDS in
infected individuals. A robust T-cell response will be a necessary
component of any successful HIV vaccine; however, the ability of
a vaccine to account for the extraordinary viral diversity of HIV-1
continues to be a challenge. This diversity extends not only to T-
cell epitope differences across clades, but also to isolates from a
number of diverse clades that occupy a single geographic area [31].
One approach to address the problem of HIV-1 diversity is to
develop multiple vaccines. These vaccines could be developed on a
clade-by-clade basis, whereby a single vaccine represents isolates
from a single clade, or on a geographically speciﬁc basis, whereby
vaccines are derived from isolates commonly circulating in a par-
ticular country or region. However, this multiple vaccine approach
raises the question of how many vaccines would be needed to pro-
tect against each of the many clades of HIV. In a time of increasing
global connectedness and mobility, the notion of controlling a par-
ticular viral population and keeping it geographically sequestered
is unlikely to bear fruit.
In  contrast to region-speciﬁc vaccine efforts, our approach is to
develop a globally effective vaccine. This vaccine would be com-
prised of epitopes targeting speciﬁc regions that are conserved
across clades and regional variations, which are considered to be
the most stable elements of the rapidly changing HIV-1 genome
[32,33]. These regions may  represent the “Achilles’ heel” of the
virus, as their persistence across time and space suggests they lie
in regions of the HIV genome that may  be resistant to selective
immunologic pressure because they ensure viral ﬁtness [34,35].
Other universal vaccine design strategies, such as the Mosaic
Vaccine Constructs and Conserved Elements concepts currently
undergoing preclinical studies, proffer global coverage based upon
consensus plus most common variants and Center-Of-Tree deriva-
tion [36–39].
“Protective” HLA class I alleles are associated with CTL responses
that target conserved regions of the viral genome located in
functional or structural domains that, when mutated, impart a
substantial ﬁtness cost on the virus [40,41]. Population-based stud-
ies have shown that the number and rate of reverting mutations
were highest in conserved residues in GAG, POL, and NEF (at
equal frequency), while escape without reversion occurred in more
variable regions [42]. Another study found that the highest ﬁt-
ness cost, based upon identiﬁcation of reverting mutations across
the entire HIV-1 subtype C proteome, occurred in target genes in
the rank order VPR > GAG > REV > POL > NEF > VIF >TAT > ENV > VPU
[42]. CD8+ CTL responses broadly targeting GAG have proven to
be important in virus control as well as elite suppression in some
individuals possessing “protective” HLA-B*57, HLA-B*5808, and
HLA-B*27 alleles [43]. It could be argued that only epitopes that can
undergo escape reversion mutations will elicit effective antiviral
responses [44,45].
The  biggest challenge for the rational design of an effective CD8+
T cell vaccine is the identiﬁcation of HLA-class I-restricted immu-
nodominant epitopes in HIV-1 that are under similar structural
and functional constraint. Therefore, our strategy for HIV-1 vaccine
design is to select epitopes that can induce broad and dominant
HLA-restricted immune responses targeted to the regions of the
viral genome least capable of mutation due to the high cost to
ﬁtness and low selective advantage to the virus. Both DeLisi and
Sette have shown that epitope-based vaccines containing epitopes
restricted by the six supertype HLA can provide the broadest pos-
sible coverage of the human population [46,47]. Thus epitopes that
are restricted by common HLA alleles and conserved over time in
the HIV genome are good targets for an epitope-based vaccine.
Previously,  we  described the identiﬁcation of 45 such HIV-1 epi-
topes for HLA-B7 [32], sixteen for HLA-A3 [48], and immunogenic
consensus sequence epitopes representing highly immunogenic
class II epitopes [49]. In this study, we focus on the identiﬁcation
and selection of highly conserved and immunogenic HLA-A2 HIV-1
epitopes. The goal is to provide valuable information and strategies
that would contribute to the development of the GAIA vaccine or
any other multi-epitope, pan-HLA-reactive, globally relevant HIV
vaccine.
The HLA-A2 supertype allele is highly prevalent in much of the
world, especially in those geographic areas under severe threat of
HIV-1. It is common among Caucasian North Americans, but slightly
less common in African American (20%) and Hispanic populations
(34%) [50]. In China, where an HIV epidemic is beginning to emerge,
HLA-A2 prevalence is 53.3% [51]. Among the African population,
HLA-A2 frequency ranges from 36% to 63% with Mali, in partic-
ular, at 43% [52]. In this study, we  present data using advanced
immunoinformatics tools to identify highly conserved putative
HLA-A2 epitopes for HIV-1. This analysis was conducted and epi-
topes were selected at two  time points: ﬁrst in 2002, and again
in 2009. These two  data sets allowed us to assess the persistence
and conservation of the selected epitopes, as the number of avail-
able HIV sequences expanded four-fold over this time period. The
immunogenicity of the 2002 and 2009 selected epitopes were con-
ﬁrmed with in vitro assays using blood from HIV-positive subjects
in Providence, Rhode Island, and Bamako, Mali.
2. Materials and methods
2.1.  Selecting a highly conserved HIV-1 sequence data set
2.1.1.  2002 sequence set
The  sequences of all HIV-1 strains published on GenBank
between January 1st, 1990, and June 2002 were obtained.
Sequences posted to GenBank prior to December 31st, 1989, were
excluded based on our observation that early sequences were more
likely to be derived from HIV clade B. Sequences shorter than 80%
and longer than 105% of a given protein’s nominal length were
also excluded. Short sequences were excluded because inclusion of
these fragments skews the selection of conserved epitopes in favor
of regions of particular interest to researchers, such as the CD4 bind-
ing domain or the V3 loop of HIV (unpublished observation). Longer
sequences were excluded because these sequences tend to cross
protein boundaries, confusing the categorization process. A second
dataset was  downloaded from the Los Alamos HIV Database using
the same criteria, and the two  datasets were merged. The combined
2002 dataset contained 10,803 unique entries selected for the next
phase of analysis.
2.1.2.  2009 sequence set
In  June–July 2009, the informatics component was repeated
to assess the extent to which the predicted epitopes had been
maintained in the expanding and evolving set of available viral
sequences. In addition, the EpiMatrix algorithm had undergone
revision which enabled it to be better at eliminating false positives
(see Section 2.1.4 below); this updated EpiMatrix was employed to
analyze the expanded sequence database. The same steps described
above were repeated with the sequences posted between January
1st, 1990, and June 30th, 2009. All other inclusion criteria were
unchanged. Due to the expansion of available HIV sequences, the
combined dataset grew from 10,803 to 43,822 sequences. At this
time we  also performed a retrospective analysis of HIV sequences
by year (Fig. 1) and selected additional epitopes (below).
L. Levitz et al. / Vaccine 30 (2012) 7547– 7560 7549
Fig. 1. Conservation for this ﬁgure was calculated by year of report from GenBank based on sequences available in 2009. Conservation data from this ﬁgure may  differ from
conservation reported in the text or in Table 1, as the number of sequences available at the time of peptide selection differs from the number available for analysis in 2009.
Sequences in each plot are listed from most to least conserved in 2009. Vertical lines have been drawn to indicate points at which peptides were identiﬁed: peptides 1237,
1247,  1249, 1257, and 1261 were identiﬁed in 1997; peptides 1001–1020 were identiﬁed in 2002; and peptides 2001–2004 and 3001–3009 were identiﬁed in 2009. Ten
peptides per protein sequence were selected at random and conservation calculated as previously described to highlight the high conservation of the epitopes chosen for
both  conservation and EpiMatrix score; mean conservation was calculated by averaging yearly conservation of the ten peptides within each protein. The second y-axis charts
the  number of protein-speciﬁc sequences available at each time point (dark, heavy lines) to demonstrate that in spite of the increased number of sequences available in 2009
as  compared to 1987, conservation of the epitopes has remained stable.
2.1.3. Conservatrix
Conservatrix was used to search the 10,803 protein sequences
from 2002 and the 43,822 protein sequences from 2009 for seg-
ments that were highly conserved among the input sequences.
Conservation evaluated in this way is a good marker for potential
high value of selected epitopes [53]. For each of the nine HIV genes,
peptides were retained for further analysis if they either were con-
served in at least 5% of the input sequences or were among the top
1000 scoring peptides, whichever criterion was  met  ﬁrst. All puta-
tive epitopes were checked for human homology by BLAST, and
those with signiﬁcant homology were excluded, a protocol that is
standard in our epitope selection process [53].
2.1.4. EpiMatrix
The  EpiMatrix algorithm was used to select peptides in 2002
from the output of highly conserved 9- and 10-mers produced by
Conservatrix [53]. Each amino acid was scored for predicted afﬁnity
to the binding pockets using the EpiMatrix HLA-A2 matrix motif.
Normalized scores were then compared to the scores of known
HLA-A2 ligands. Peptides scoring higher than 1.64 on the EpiMa-
trix Z scale (the top 5% of all scores on the normalized scale) were
selected. This cutoff falls within the same Z-score range as pub-
lished HLA-A2 epitopes, and therefore these selected sequences
serve as good predictions of binding to HLA-A2 and represent
the most useful potential candidates for inclusion in an HIV vac-
cine. Although not designed to be so, the selected peptides are
all predicted to be potentially promiscuous binders, as they are
predicted to bind alleles within the HLA-A2 supertype as well as
many additional MHC-1 alleles. Additionally, epitopes originally
selected in 1997 for their estimated binding potential (EBP) [54]
were re-screened for putative binding to HLA-A2 using the Epi-
Matrix HLA-A2 matrix as described above, The selected peptides
were validated with in vitro HLA-A2 binding assays, and their abil-
ity to elicit IFN responses in PBMC cultures from HIV-1 infected
individuals was assessed by ELISpot.
The  EpiMatrix HLA-A2 matrix motif was  retrained on a more
robust set of A2 epitopes using the expanded set of sequences
available in 2009. This updated matrix is believed to be more accu-
rate than the 2002 matrix and has demonstrated high prediction
accuracy when benchmarked against other prediction tools [55].
The updated EpiMatrix algorithm was  used in 2009 to scan the
expanded number of available HIV sequences for putative bind-
ing to HLA-A2, with the goal of reevaluating previously selected
epitopes and identifying new candidate epitopes to be considered
for inclusion in a global HIV vaccine.
2.1.5. Epitope selection
An  initial set of 25 peptides, including ﬁve epitopes originally
identiﬁed in 1997 [54], was  selected in 2002 for putative bind-
ing to HLA-A2 as measured by EpiMatrix score. The 2002 list of
peptides consisted of six epitopes from ENV, four from GAG, nine
from POL, two from VIF, and one each in TAT, NEF, VPR, and VPU.
HIV sequences available in June 2009 were re-evaluated for puta-
tive binding to HLA-A2. This analysis differed from that in 2002 in
two important ways: it used the improved EpiMatrix algorithm and
drew from a database of HIV sequences that had expanded four-fold
since 2002. Thirteen new highly conserved HLA-A2 epitopes were
identiﬁed and selected for validation studies, including two pep-
tides from ENV, four from REV, three from VIF, and one each from
GAG, POL, NEF, and VPU. Fourteen epitopes from the 2002 epitope
set were reselected in 2009 for validation in Mali in in vitro stud-
ies based on updated EpiMatrix scores and peptide availability. The
complete list of peptides tested in this report is shown in Table 1.
2.2. Peptide synthesis
Peptides  corresponding to the 2002 epitope selections were
prepared by 9-ﬂuorenylmethoxycarbonyl (Fmoc) synthesis on
an automated Rainin Symphony/Protein Technologies synthesizer
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Table 1
Overview of EpiMatrix-predicted HLA-A2 restricted epitopes for inclusion in the GAIA Vaccine.
Study ID Sequence Conservation in
contemporary
proteins
Earliest infection
year
Countries  covered
(of  239)
Top three clades
represented
EpiMatrix score at
study  inclusion
In vitro soluble
assay  Kd (nM)
% donors responding
positively in ELISpots
Published prior to
selection?  For A2?
Published since
selection  (as of May
2012)?  For A2?
Peptides selected for study in 2002 (2002 EpiMatrix score is reported):
POL 1007 KLAGRWPVKV 40% 1976 55 C, 01 AE, A1 3.55 1.4 0.0% N Y
ENV  1001 GIKPVVSTQL 43% 1976 80 C, B, 01 AE 3.13 – 20.8% N N
GAG  1012 RMYSPVSIL 53% 1976 82 C, B, 01 AE 3.63 1.3 33.3% N Y, A2
ENV 1003 RLRDLLLIV 29% 1979 41 B, BF, 01B 3.05 161.2 6.3% Y, A2 Y, A2
POL  1011 KLVGKLNWA 87% 1976 74 B, C, 01 AE 2.84 1.0 12.5% Y, A2 Y, A2
POL 1006 ALQDSGSEV 46% 1984 61 B, C, 01 AE 3.79 1.9 16.7% N Y, A2
ENV 1005 SLCLFSYHRL 44% 1979 74 B, C, 01 AE 2.91 21.9 25.0% N Y
VPR 1019 ETYGDTWTGV 28% 1982 37 B, C, D 2.49 3.5 8.3% N Y
GAG 1013 ELKSLYNTV 14% 1980 56 B, C, A1 3.57 801.5 20.8% N Y
POL 1247 HLKTAVQMAV 96% 1976 75 B, C, 01 AE 3.58 80.9 31.3% N Y, A2
ENV 1004 TMGAASITL 42% 1976 75 C, B, 01 AE 2.96 6.7 25.0% N Y, A2
ENV  1002 AVLSIVNRV 42% 1979 70 B, C, 01 AE 3.08 2.5 20.8% N Y
POL 1008 ELKKIIGQV 66% 1976 68 B, C, 01 AE 3.43 4783.9 33.3% N Y
VPU  1020 TMVDMGHLRL 1% 1987 6 CD, A2 C, C 3.11 1.0 11.8% N Y
VIF 1018 KISSEVHIPL 25% 1976 51 B, C, D 2.93 140.2 12.5% N N
ENV  1257 NMWQEVGKAM 33% 1979 41 B, C, D 3.05 24.0 25.0% Y, A2 Y, A2
GAG 1014 MLKETINEEA 46% 1980 47 B, 01 A3, D 3.14 1.2 20.8% Y Y
NEF 1015 WLEAQEEEEV 47% 1981 54 B, A1, C 3.32 137.1 6.3% N Y
GAG 1261 SLYNTVATLY 31% 1976 59 B, C, A1 3.89 nt 33.3% Y, A2 Y, A2
POL  1016 GLKKKKSVTV 65% 1982 74 B, C, 01 AE 3.56 1372.5 0.0% Y N
POL 1009 ELAENREIL 84% 1976 75 B, C, 01 AE 3.18 2237.5 12.5% Y, A2 Y
POL 1010 DIQKLVGKL 87% 1976 74 B, C, 01 AE 2.97 – 6.3% N Y
POL 1249 ILKEPVHGVY 71% 1976 69 B, C, 02 AG 4.61 nt 44.4% Y, A2 Y, A2
VIF  1237 DLADQLIHLY 18% 1981 37 B, A1, 02 AG 3.45 42.8 25.0% N Y, A2
TAT 1017 RLEPWKHPG 31% 1981 37 B, BF1, BF 2.19 – 6.3% N N
Peptides  selected for study in 2009 (2009 EpiMatrix score is reported):
ENV 3002 WLWYIKIFI 77% 1976 87 B, C, 01 AE 3.14 nt 12.5% Y, A2 Y, A2
REV 2002 ILVESPTVL 9% 1983 18 B, BF, 03 AB 2.92 58.4 25.0% N N
NEF  3004 LTFGWCFKL 73% 1981 65 B, C, A1 2.92 280.6 25.0% Y, A2 Y, A2
VIF  3008 SLVKHHMYI 35% 1981 54 B, C, 01 AE 2.51 24.5 37.5% Y, A2 Y, A2
REV  2004 PLQLPPLERL 47% 1981 63 B, 01 A3, C 2.51 – 50.0% Y N
POL 3005 YQYMDDLYV 82% 1976 75 B, C, 01 AE 2.30 1.4 37.5% Y, A2 Y
REV  2001 GVGSPQILV 13% 1982 25 B, 01B, BF 2.28 8965.1 37.5% N N
VIF  3007 SLQYLALTA 46% 1976 66 B, C, D 2.19 41.2 37.5% N N
REV 2003 SAEPVPLQL 15% 1983 44 B, C, 02 AG 2.17 – 50.0% Y Y
ENV  3001 QLLLNGSLA 93% 1976 87 A1, B, D 2.04 812.7 37.5% Y N
VPU  3009 KIDRLIDRI 34% 1980 36 B, BF1, BF 1.92 824.1 0.0% N N
GAG  3003 RTLNAWVKV 97% 1976 83 B, C, 07 BC 1.86 nt 25.0% Y, A2 N
VIF 3006 KVGSLQYLA 84% 1976 78 B, C, 01 AE 1.81 463.6 62.5% N N
Thirty-eight peptides were identiﬁed as putative A2 epitopes for assessment and potential inclusion in an HIV vaccine; based on this study, 32 peptides were deﬁned as A2 epitopes and 6 as potential A2 epitopes in need of further
deﬁnition.  Peptides were selected for this study in 1997 (peptides 1237, 1247, 1249, 1257, and 1261), in 2002 (peptides 1001–1020), or in 2009 (peptides 2001–2004 and 3001–3009) based on their high conservation and high
putative  immunogenicity for A2. The ﬁve peptides identiﬁed in 1997 were evaluated using the 2002 EpiMatrix HLA-A2 algorithm and selected for study inclusion in 2002. Peptide 1261 (SLYNTVATLY) was chosen to serve as a
positive  control for the in vitro binding assays and CTL assays. All peptides were given a unique identifying number, displayed in column 1. Peptide source proteins are also displayed in column 1: there were 12,233 sequences
from  ENV, 5623 sequences from GAG, 8361 sequences from NEF, 2147 sequences from POL, 2580 sequences from REV, 2348 sequences from TAT, 3242 sequences from VIF, 3850 sequences from VPR, and 3437 sequences from
VPU.  Peptide sequences are shown in column 2. Column 3 shows the percent conservation of each peptide among its respective number of input strains from the year the peptide was selected. The earliest infection year, shown
in  column 4, was based on year of report from LANL or GenBank and may have been identiﬁed retroactively from samples collected prior to the discovery of HIV; all of the peptides cover strains present at least as recently as 2009.
Column  5 shows the number of countries in which strains are covered by each of the peptides from a total of 239 countries identiﬁed by the GenBank database. Column 6 shows the three clade subtypes most frequently covered
by  each peptide; clades classiﬁed as “unknown” were excluded from this analysis. Column 7 displays the peptide’s HLA-A2 EpiMatrix score at the time of study selection in either 2002 or 2009. Column 8 details the results of
in  vitro HLA-A2 binding assays. Kd scores in nM are interpreted as follows: Kd < 5 is a very high-afﬁnity binder; 5 < Kd < 50 is a high-afﬁnity binder; 50 < Kd < 500 is an intermediate-afﬁnity binder; 500 < Kd < 5000 is a low-afﬁnity
binder; and 5000 < Kd is a non-binder. Non-binding peptides are indicated with a dash in this column; peptides not tested in binding assays are denoted by “nt”. Column 9 displays the results of ELISpot assays performed in
Providence  and in Mali, respectively; details can be found in Table 3. Columns 10 and 11 indicate whether the peptide has been published prior to or after selection for our study; if the peptide has been published, this column
also  indicates whether A2 was  included as an allele for which the peptide was  restricted.
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(Synpep, Dublin, CA). The peptides were delivered 90% pure as
ascertained by HPLC.
Peptides  corresponding to the 2009 epitope selections were
prepared by solid-phase Fmoc synthesis on an Applied Biosys-
tems/Perceptive Model Pioneer peptide synthesizer (New England
Peptide, Gardner, MA). The peptides were delivered >80% pure as
ascertained by HPLC, matrix-assisted laser desorption/ionization
(MALDI) mass spectrometry, and UV scan at wavelengths of 220
and 280 (ensuring purity, mass, and spectrum, respectively).
2.3.  Puriﬁed HLA class I binding assay
The MHC  class I binding assays were performed as previously
described [56]. The HLA class I molecule was incubated at an active
concentration of 2 nM together with 25 nM human 2 microglob-
ulin (2 m)  and an increasing concentration of the test peptide
at 18 ◦C for 48 h. The HLA molecules were then captured on an
ELISA plate coated with the pan-speciﬁc anti-HLA antibody W6/32,
and HLA-peptide complexes were detected with an anti-2 m spe-
ciﬁc polyclonal serum conjugated with horseradish peroxidase
(Dako P0174), followed by a signal enhancer (Dako Envision). The
plates were developed, and the colorimetric reaction was  read at
450 nm using a Victor2 Multilabel ELISA reader. Using a standard,
these readings were converted to the concentration of HLA-peptide
complexes generated and plotted against the concentration of
test peptide offered. The concentration of peptide required to
half-saturate (EC50) the HLA was determined. At the limiting
HLA concentration used in the assay, the EC50 approximates
the equilibrium dissociation constant, KD. The relative afﬁnities
of peptides, based on a comparison of known HLA-A2 ligands,
were categorized as high binders (KD < 50 nM), medium binders
(50 nM < KD > 500 nM), low binders (500 nM < KD > 5000 nM), and
non-binders (KD > 5000 nM). Binding scores for each of the selected
peptides can be found in Table 1.
2.4. Blood samples
Interferon gamma ELISpot assays were performed using periph-
eral blood mononuclear cells (PBMCs) separated by Ficoll density
gradient centrifugation of whole blood. HIV-seropositive sub-
jects living in Providence, Rhode Island, and Bamako, Mali, were
recruited in accordance with all federal guidelines and institutional
policies. Institutional review boards in Providence and Bamako,
Mali, approved the informed consent procedures and research pro-
tocols at each of the sites. Informed consent was obtained prior to
obtaining all samples for this study.
2.5. Study cohorts
Patient  study cohorts were from two geographically distinct
locations: Providence, Rhode Island, and Bamako, Mali. The Provi-
dence study subjects belonged to two cohorts (cohort #1 and cohort
#2) of long-term slow or non-progressors (CD4 > 350 for >10 years
with minimal or no treatment) or from chronically HIV-infected
patients (CD4 > 350 and not on treatment). Subjects in cohort one
were recruited from an HIV clinic at the Miriam Hospital in Prov-
idence, Rhode Island, and were used to validate epitopes selected
in 2002. Subjects in cohort #2 were HIV-seronegative donors from
the Rhode Island Blood Center (RIBC) and were used to validate epi-
topes initially identiﬁed in 1997 and reselected in 2002. Subjects
in cohort #3 were HIV-1 infected, otherwise healthy (CD4 > 350)
volunteers recruited from the Bloc Espoir clinic situated in Sikoro,
Bamako, Mali; these subjects were used to validate epitopes that
were either newly identiﬁed or reselected for study inclusion in
2009.
HLA typing was performed by the Transplant Immunology
Laboratory at Hartford Hospital and the Faculty of Science and Tech-
nology at the University of Bamako using the Micro SSP HLA  Class
I DNA typing tray (One Lambda Inc., Canoga Park, CA).
2.6.  ELISpot assays
The  frequency of epitope-speciﬁc T lymphocytes was deter-
mined using Mabtech® IFN ELISpot kits according to the
manufacturer’s instructions (Mabtech, Sweden). Washed PBMCs
from each donor were added at 2.5 × 105 cells per well to 96-
well ELISpot plates pre-coated with anti-IFN antibody. Individual
peptides were added to the ELISpot plate at 10 g/ml, as well as pos-
itive controls PHA (10 g/ml) and the CEF peptide pool (10 g/ml).
In assays done in Mali in 2009–2010, the CEF peptide pool was
replaced with a pool of all tested HIV peptides. Six to twelve wells
of PBMCs per plate were cultured without peptide to measure back-
ground. The ELISpot plates were incubated overnight at 37◦C, and
then washed with PBS. Following the washes, biotinylated anti-
IFN was  added, followed by streptavidin-HRP. ELISpot plates were
developed by the addition of ﬁltered TMB  substrate. The frequency
of antigen-speciﬁc cells was  calculated as the number of spots per
106 PBMCs seeded. Responses were considered positive if the num-
ber of spots was at least twice background and was  also greater
than twenty spots per million cells over background (one response
over background per 50,000 PBMCs). The relatively lower num-
ber of spots seen can be expected when stimulating cells directly
ex vivo with peptide, as compared to the larger responses seen
when cells are stimulated with whole protein or peptide, incubated
for several days, and then re-stimulated. We considered positive
results obtained by these two criteria to be more stringent. Sta-
tistical signiﬁcance was determined at p < 0.05 by the two-tailed,
non-parametric Mann–Whitney U-test comparing the number of
spots in the peptide wells with the number of spots in the control
wells.
3. Results
3.1. Epitope mapping and selection
Based on criteria described in the methods, 38 HLA-A2 pep-
tides chosen for this study in 2002 or 2009 had EpiMatrix Z-scores
between 1.81 and 4.61 at the time of selection. Notably, ﬁve of these
peptides, initially identiﬁed in 1997 for their estimated binding
potential (EBP; precursor to EpiMatrix scores), were selected for the
current study after reanalysis with the 2002 EpiMatrix algorithm,
which revealed EpiMatrix Z-scores ranging from 3.05 to 4.61. Since
HIV sequence space has been well mapped for HLA-A2 epitopes, it is
not surprising that sixteen of the peptides selected using EpiMatrix
had been published when they were selected for inclusion in our
prospective in vitro studies. Five of these sixteen sequences were
previously published as binders to alleles other than HLA-A2 (see
Table 1) but were not reported as epitopes for HLA-A2. Fourteen of
the remaining 22 peptides that were novel at selection have since
been published in the literature after we  performed the analysis
(2002 and 2009); again, this is not surprising and reinforces the
utility of the approach for HLA-A2, which can be applied to other
HLA alleles. In this study, we  were able to identify eight novel, as
yet unpublished HLA-A2 epitopes.
3.2. Conservation of HLA-A2 epitopes over time and sequence
space
Overall stability is evident for each of the A2 epitopes selected
using a dual conservation-putative binding score approach (Fig. 1).
Even as the number of protein sequences has increased signiﬁcantly
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Fig. 2. Conservation of the HIV HLA-A2 peptides, both individually and in aggregate, across years, countries, and clades. Each row of the matrix denotes a speciﬁc peptide,
named by the peptide’s protein of origin and its speciﬁc ID number. Each column of the matrix represents a speciﬁc year, country, or clade, grouped as indicated. The
percentage coverage of strains is represented on a color gradient, with blue indicating values in the 10th percentile, yellow indicating values in the 40th percentile, and red
indicating values in the 80th percentile. Black boxes indicate that no isolates of the protein were available for that year, clade, or country. The bottom row represents the
aggregate percent coverage for the set of 38 epitopes. Each cell of the matrix represents the percent coverage per peptide, except for the bottom-row cells, which represent
the aggregate percent coverage for the peptide set. Column headers are listed here for space considerations: left to right, the year columns are 1980–2009; aggregate coverage
of  strains by year ranges from 24% (1980) to 58% (1982). The countries left to right are: Afghanistan, Angola, Argentina, Austria, Australia, Belgium, Burkina Faso, Burundi,
Benin, Bolivia, Brazil, Botswana, Belarus, Canada, the Democratic Republic of the Congo, the Central African Republic, Congo, Switzerland, the Ivory Coast, Chile, Cameroon,
China, Colombia, Cuba, Cyprus, Germany, Djibouti, Denmark, Dominica, the Dominican Republic, Ecuador, Estonia, Spain, Ethiopia, Finland, France, Gabon, Great Britain,
Georgia, Greenland, Guinea, Equatorial Guinea, Greece, Hong Kong, Haiti, Indonesia, Israel, India, Italy, Jamaica, Japan, Kenya, Cambodia, South Korea, Kazakhstan, Liberia,
Luxembourg, Mali, Myanmar, Malawi, Malaysia, Namibia, Niger, Nigeria, the Netherlands, Norway, Peru, Paraguay, Qatar, Reunion, Romania, the Russian Federation, Rwanda,
Saudi  Arabia, San Marino, Senegal, Somalia, Chad, Turkey, Trinidad & Tobago, Taiwan, Tanzania, Ukraine, Uganda, the United Kingdom, the United States, Uruguay, Uzbekistan,
Venezuela, Yemen, South Africa, Zambia, and Zimbabwe; aggregate coverage of strains by country ranges from 15% (Equatorial Guinea) to 84% (Malaysia). The clades left
to  right are: 01 AE, 0102A, 01A1, 01ADF2, 01AF2U, 01B, 01BC, 01C, 01DU, 01GHJKU, 02 AG, 02A, 02A1, 02A1U, 02B, 02C, 02D, 02G, 02GK, 02O, 02U, 03 AB, 04 CPX, 05 DF,
06  CPX, 06A1, 07 BC, 07B, 08 BC, 09 CPX, 09A, 09A1KU, 10 CD, 11 CPX, 12 BF, 13 CPX, 13U, 14 BG, 15 01B, 16 A2D, 17 BF, 18 CPX, 19 CPX, 20 BG, 21 A2D, 22 01A1, 23 BG,
23A1, 24 BG, 25 CPX, 27 CPX, 28 BF, 29 BF, 31 BC, 32 06A1, 33 01B, 34 01B, 35 AD, 36 CPX, 37 CPX, 38 BF1, 39 BF, 40 BF, 42 BF, 43 02G, A, A/G, A1, A1A2D, A1B, A1C, A1CD,
A1CDGKU, A1CG, A1D, A1DHK, A1F2, A1G, A1GHU, A1GJ, A1GU, A1U, A2, A2C, A2CD, A2D, A2G, A3, AC, ACD, AD, ADGU, ADU, AE, AF2, AF2G, AG, AGH, AG-Ibng, AGU, AHJU,
AKU, B, B’, B,C, BC, BCF1, BCU, BF, BF1, BG, C, CD, CGU, CRF01 AE, CRF01 AE/B, CRF01-AE, CRF02, CRF02 AG, CRF06 cpx, CRF07 BC, CRF12 BF, CRF15 01B, CRF16 A2D, CRF17 BF,
CRF21  A2D, CRF25 AGU, CRF34 01B, CRF35 AD, CRF37 cpx, CRF39 BF, CU, D, D/A, DU, E, E/A, F, F1, F2, F2KU, G, GKU, H, J, JU, K, L, N, O, and U; aggregate coverage of strains
by clade ranges from 4.5% (O) to 100% (CGU).
over the period from 1987 to 2009, the prevalence of each epitope
within those protein sequences has remained relatively constant.
This data demonstrates that the set of selected HLA-A2 epitopes
is evolutionarily conserved and has now become relatively stable
within the diversity of HIV sequences. For each year from 1987
through 2009, conservation is calculated retrospectively as the pro-
portion of each HIV epitope to the total number of sequences within
the epitope’s protein of origin available for that year. Level trends
across the evolutionary landscape indicate stable targets.
The  most highly conserved HLA-A2 binding peptide found in this
analysis was GAG-3003 (97% conserved over the evolutionary land-
scape). This epitope, located in GAG p2419-27 TLNAWVKVV (TV9), is
a well-deﬁned HLA-A2-restricted epitope located in helix 1 of the
capsid protein. It overlaps the well-known B*57 IW10 epitope and
may  be under some functional constraint, although mutations are
tolerated in this helix whereas mutations in helices two and eight
are not. CTL targeting the HLA-A2 epitope are subdominant but are
reported to be high avidity [57].
For the selected envelope peptides, ENV-3001 was present in
the greatest proportion of published envelope sequences, repre-
sented in 95% of the 258 envelope sequences available in 1987. By
2009, though the number of envelope protein sequences increased
more than 47-fold to 12,233, the proportion of sequences contain-
ing the ENV-3001 epitope remained at 93% (Fig. 1). For comparison,
GAG-1261, which corresponds to the classical immunodominant
HLA-A2-restricted GAG p1777-85 SLYNTVATL epitope, has been
shown to be under strong selective pressure in HIV-1-infected
individuals expressing HLA-A2 and shows signiﬁcantly less con-
servation (31%). Overall, the HLA-A2 selected epitopes in POL show
the highest conservation. VPR, VPU, and REV epitopes have the low-
est total conservation, which is consistent with the high Shannon
entropy in these protein sequences [58,59].
In the course of this analysis we identiﬁed two immunogenic
sequences in GAG, 1012 and 1014, which appear to change in con-
servation over time in an inverse relationship to one another. As
1012 conservation increases, 1014 conservation decreases. While
there is no obvious structural relationship that explains the com-
pensatory mutations (1012 is part of helix 7 and 1014 is part of
helix 4), it is worth noting that Tang et al. have recently proposed
a possible structural connection [60]. It is unlikely that the directly
inverse relationship between GAG sequences is entirely random.
3.3.  Conservation of HLA-A2 epitopes across years, clades, and
countries
The  conservation of the selected A2 epitopes across years,
clades, and countries is shown in Fig. 2. Each column of the matrix
represents the set of HIV proteins that falls into a given category
(year isolated, clade, or country), while each row of the matrix rep-
resents a single 9-mer or 10-mer that was selected as an A2 epitope.
The bottom row of cells represents the aggregate percent coverage
for the set of 38 epitopes. This set of highly conserved A2-restricted
peptides covered between 33% (2007) and 100% (1980) of strains
in a given year, between 15% (Equatorial New Guinea) and 84%
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(Malaysia) of strains in a given country, and between 5% (clade O)
and 100% (clade CGU) of strains in a given clade, with mean con-
servations of 55%, 48%, and 45%, year, country, clade, respectively.
This represents remarkable breadth of coverage for a limited set
of HLA-A2 epitopes, given the well-known ability of HIV to mutate
away from HLA-A2 [61,62].
3.4. In vitro peptide binding to soluble HLA-A2
Thirty-four of the selected peptides were evaluated for binding
to HLA-A2 in vitro using a soluble HLA-A2 binding assay (Table 1).
The remaining four peptides were not tested in these assays due to
limited peptide availability. Fifteen of the 34 peptides tested bound
with high afﬁnity (44%), seven bound at intermediate afﬁnity (21%),
six bound at low afﬁnity (18%), and six showed no detectable bind-
ing (18%). We  note as a mark of speciﬁcity that in previous binding
studies, none of eight B7- or A11-restricted peptides [54] and none
of 18 B27-restricted peptides [63] bound to HLA-A2. Fourteen of the
ﬁfteen peptides predicted as high-afﬁnity binders generated posi-
tive ELISpot results in PBMCs from HIV-infected subjects. One of the
ﬁfteen peptides, POL-1007, did not stimulate any IFN response in
this cohort in spite of its very high predicted and observed binding
afﬁnity for A2. This peptide was part of a longer peptide previously
published as HIV-VAX-1047, an immunogenic consensus sequence
for MHC  class II binding to DRB 0101 [64].
Several peptides elicited positive IFNELISpot responses in spite
of their low in vitro HLA-A2 binding afﬁnity (Table 1). It is possible
that these epitopes were presented in the context of other HLA
alleles in those subjects. In support of this hypothesis, an EpiMatrix
analysis predicts that several of these epitopes are able to bind to
other class I alleles. However, as not all of the HLA alleles for each
subject were identiﬁed for this study, we are unable to compare
alternate predicted binding with the subjects’ alleles.
3.5.  Subjects
Subjects are listed in Table 2 along with their corresponding
viral loads, CD4 T-cell counts, and years since ﬁrst identiﬁed as
infected. Subjects were on antiretroviral therapy as indicated. A
criterion for entry into the study was a detectable viral load below
10,000 copies/ml, as we have observed that subjects with unde-
tectable viral loads also have very low CTL responses. Information
on resistance, clinical course, and further details on the stage of dis-
ease was not recorded in the initial study (initiated in 2002). Other
than HIV infection, all subjects were otherwise healthy at the time
they were recruited.
A  total of 24 HIV-infected subjects were recruited from clin-
ics in Providence, Rhode Island. Sixteen HIV-infected subjects
(study subject cohort #1) were recruited from the Miriam Hospital
Immunology Center (Table 2a). Eight HIV-infected subjects (study
subject cohort #2) were recruited from clinics at Roger Williams
Hospital and Pawtucket Memorial Hospital; complete clinical infor-
mation was not available for these donors (Table 2b). Eight HIV-1
positive subjects (study subject cohort #3), who had been infected
for less than a year and were not receiving ART at the time of enroll-
ment in the study, were recruited from the Bloc Espoir HIV Clinic
in Sikoro, Bamako, Mali (Table 2c).
3.6. ELISpot assays
3.6.1.  United States and Mali
Immunoreactivity of predicted HLA-A2 epitopes in HIV-infected
subjects was evaluated in the United States following immunoin-
formatic analysis in 2002 and in Mali following the 2009 analysis.
Twenty-ﬁve epitopes were assessed in United States studies,
of which fourteen were selected for testing in Mali, based on
EpiMatrix  scores, binding assay results, and peptide availability.
Mali studies included an additional thirteen newly identiﬁed puta-
tive epitopes, for a total of 27 epitopes assessed there. Of  the
fourteen epitopes tested in both the United States and Mali, eleven
(79%) stimulated a positive IFN ELISpot response in at least one
patient from each of the geographically distinct areas. Four of ﬁve
ENV peptides (80%), three of three GAG peptides (100%), three of
four POL peptides (75%), and the one VIF peptide (100%) tested gen-
erated a positive response in subjects from Providence and Mali. An
additional three peptides—one each in ENV, POL, and VPR—elicited
positive responses in Mali only. The 27 epitopes chosen in 2009
were also assessed in ELISpot assays with ﬁve HIV-positive donors
who were conﬁrmed to be HLA-A2 negative. Four of the ﬁve donors
(80%) had no positive IFN responses to any of the 27 peptides
tested; one donor responded to only one of 27 (3.7%) peptides
tested, demonstrating HLA-A2 speciﬁcity of the peptides selected
for our present study.
For  the cohorts of chronically HIV-1-infected subjects from both
the Miriam Hospital and the clinic in Bamako, Mali, there was  no
clear association between viral load, CD4 T-cell count, or years of
known HIV infection with responses to HLA-A2 epitopes. In addi-
tion, no clear association was  found between having multiple A2
alleles and the number of epitopes that elicited a detectable IFN
ELISpot result for a given donor. It is worth noting that, in gen-
eral, the subjects from Mali had an impressive number of epitope
responses compared to the Providence subjects (Table 3a–c). One
patient in this group responded to 25 epitopes, and four others with
low viral loads responded to a mean of eleven epitopes. It is possible
that this is due to the fact that these subjects were recruited for the
study less than a year after they had been identiﬁed as HIV-positive
and/or due to the correlate that none of the study participants in
Mali had yet received long-term antiretroviral therapy. Notably, the
one Providence subject (H 0865) who  was  not receiving ART, yet
had a low viral load, responded to eight HLA-A2 epitopes.
3.6.2. Comparison with published HLA-A2 epitopes
The ELISpot analysis reconﬁrmed eleven epitopes that were
published for HLA-A2 prior to the time of selection for this study
(Table 1). Five of the epitopes that were initially identiﬁed and
predicted by our 2002 informatics analysis as entirely novel HLA-
A2 epitopes have subsequently been validated as A2-restricted
epitopes by others (Table 1). These epitopes are ENV-1004 (TMGA-
ASITL) [65], GAG-1012 (RMYSPVSIL) [66], POL-1006 (ALQDSGSEV)
[67], POL-1247 (HLKTAVQMAV) [54], and VIF-1237 (DLADQLIHLY)
[54]. Thus sixteen of the 38 epitopes have been validated by both
our group and by other laboratories as HLA-A2 epitopes. In addition,
assays conﬁrmed ﬁve peptides that had been published epitopes
prior to selection for inclusion in our study, although they were
not published in the context of HLA-A2 (Table 1). Four of these
epitopes were immunogenic in ELISpot assays with PBMCs from
HLA-A2 subjects, and while only two  of these epitopes were tested
in in vitro binding assays, both bound to HLA-A2. The ﬁfth epitope,
POL-1016 (GLKKKKSVTV) [67], did not elicit positive IFN ELISpot
responses in any subjects yet was  shown to bind to HLA-A2 with
low afﬁnity, indicating that this may still be a relevant candidate
for inclusion in a global vaccine (Table 1).
Since their original selection in the 2002 informatics analy-
sis of novel peptides, 14 of the 22 novel epitopes have been
published, nine of which have not been published with HLA-
A2 restriction (Table 1). Of the nine peptides in this group,
eight elicited IFN ELISpot responses in PBMCs from HIV-1-
infected subjects possessing A2 alleles: ENV-1002 (AVLSIVNRV)
[49], ENV-1005 (SLCLFSYHRL) [49], GAG-1013 (ELKSLYNTV) [68],
NEF-1015 (WLEAQEEEEV) [69], POL-1008 (ELAENREIL) [70], POL-
1010 (DIQKLVGKL) [70], VPR-1019 (ETYGDTWTGV) [71], and
VPU-1020 (TMVDMGHLRL) [70].
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Table 2
HIV-infected subjects (3 cohorts): Immune responses to the HLA-A2-restricted GAIA Vaccine candidate epitopes.
Table 2a Study subject cohort #1 (Providence, RI, USA)
Patient  ID Most  recent
viral  load
Most  recent
CD4  count
Years  since ﬁrst
identiﬁed  as
infected
On  ARV
treatment
Number of positive
epitope  responses
HLA-A  alleles
H 0863 I 102802 <50 809 4 Yes 3/20 A02011, A3001
H  0911 I 120203 <75 321 19 Yes 0/20 A0201
H  0848 I 100702 112 803 7 Yes 0/20 A02022, A03011
H  0865 I 102902 266 689 13 No 8/20 A02011
H 0852 I 100702 372 391 14.3 Yes 0/20  A02011
H 0845 I 100102 535 580  13 Yes 0/20 A02011, A3001
H 0881 I 012803 621 626 17 Yes 0/20 A02011, A29011
H  0834 I 091602 766 430 18 Yes 0/20 A02011, A66011
H  0836 I 091702 847 380 N/A Yes 3/20 A02011, A2901
H  0833 I 010703 1098 1064 2.5 No 1/20 A0201, A0801
H 0856 I 101502 1233 617 14 Yes 0/20 A01011, A02011
H  0854 I 101502 2441 623 8 No 2/20 A02011, A3401
H 0912 I 120303 4177 316 8 Yes 11/20 A0201
H  0840 I 092302 5923 483 7 No 0/20 A02011, A03011
H 0843 I 100102 32,925 428 11 Yes 2/20 A02011, A7401
H  0858 I 011403 77,350 500 10 No 1/20 A02011, A2603
Table  2b Study subject cohort #2 (Providence, RI, USA)
Patient  ID Most recent
viral  load
Most recent
CD4  count
Years since ﬁrst
identiﬁed  as
infected
On ARV
treatment
Number of positive
epitope  responses
HLA-A alleles
0902991 <10,000 >200 N/A N/A 3/5 A2, A30
H0014M <10,000 >200 N/A N/A 3/5 A1, A2
0517001  <10,000 >200 N/A N/A 2/5 A2, A3
H0023M  <10,000 >200 N/A N/A 2/5 A2, A30
0906002  <10,000 >200 N/A N/A 1/5 A2, A3
0829001  <10,000 >200 N/A N/A 0/5 A2, A3
H0007M  <10,000 >200 N/A N/A 0/5 A2, A29
H0204R  <10,000 >200 N/A N/A 0/5 A2
Table  2c Study subject cohort #3 (Bamako, Mali)
Patient ID Most recent
viral  load
Most recent
CD4  count
Years since ﬁrst
identiﬁed  as
infected
On ARV
treatment
Number of positive
epitope  responses
HLA-A alleles
0015267 <25 1218 <1 No 16/27 A0231, A0285, A0286, A9206, A0279
0015299 <400 471 <1 No 13/27 A0208
0018341  2541 689 <1 No 4/27 A0280, A0241, A0208
0018349 4700 674 <1 No 14/27 A0208
0018322  110,000 1443 <1 No 5/27 A0250, A0258, A0265, A0273
0015269 226,000 796 <1 No 2/27 A0209, A0231
0015420  445,000 364 <1 No 0/31 A0263, A0214
0015404  N/A 303 <1 No 25/27 A02, A0285, A0286
Table 2a HIV-1-positive HLA-A2 subjects were recruited at the Miriam Hospital Immunology Center in Providence, Rhode Island. The subjects are listed in column 1 and are
displayed  by lowest viral load to highest viral load, as shown in column 2. Subjects’ most recent CD4 counts are shown in column 3. Column 4 shows the number of years of
known HIV-1 infection for each subject. These subjects were on antiretroviral therapy as indicated in column 5. PBMCs from these subjects were evaluated for IFN secretion
in  response to each of 20 A2 peptides (1001–1020); the number of epitopes to which each patient responded is shown in column 6. All subjects were HLA-A2-positive, and
HLA-A subtypes are shown in column 7. Fifteen of the 20 peptides stimulated a positive response in at least one subject. Eight of the 16 subjects (50%) responded to at least
one  of the peptides.
Table  2b HIV-1-positive HLA-A2 subjects were recruited at Roger Williams Hospital and Pawtucket Memorial Hospital in Rhode Island, or from clinics in Massachusetts. The
subjects  are listed in column 1. Other than HLA-A typing, no clinical information is available for individual subjects within this cohort. Though viral loads and CD4 counts
(columns 2 and 3, respectively) by donor are unavailable, the criteria for entry into this study cohort were a detectable viral load below 10,000 copies/ml and an absolute
CD4T cell count above 200 cells per Cl. Information on duration of HIV infection and ARV treatment status, displayed in columns 4 and 5, respectively, was not accessible.
PBMCs from these subjects were evaluated for IFN secretion in response to each of 5 A2 peptides (1237, 1247, 1249, 1257, and 1261); the number of epitopes to which
each patient responded is shown in column 6. All subjects were HLA-A2 positive, and HLA-A subtypes are shown in column 7. Each of the ﬁve peptides stimulated a positive
response in at least one subject. Two peptides, 1261 and 1249, generated positive responses in three out of eight subjects (37.5%) and two  peptides, 1257 and 1237, stimulated
a  positive response in two  out of eight subjects (25%). Peptide 1247 was  positive in only one subject in this cohort.
Table 2c HIV-1-positive HLA-A2 subjects were recruited at the Bloc Espoir clinic in Sikoro, Bamako, Mali. The subjects are listed in column 1 and are displayed by lowest
viral load to highest viral load, as shown in column 2. Viral load data was  unavailable for one subject, patient 0015404. Subjects’ most recent CD4 counts are shown in
column 3. Column 4 shows the number of years of known HIV-1 infection for each subject. None of these subjects were on antiretroviral therapy, as indicated in column
5. PBMCs from these subjects were evaluated for IFN secretion in response to each of 27 A2 peptides (1001, 1002, 1004–1006, 1008, 1011–1014, 1019, 1237, 1247, 1257,
2001–2004, and 3001–3009). PBMCs from one subject (0015420) were tested with the same set of 27 peptides, plus four additional peptides (1007, 1020, 1249, and 1261).
The number of epitopes to which each patient responded is shown in column 6. All subjects were HLA-A2-positive, and HLA-A subtypes are shown in column 7. Twenty-six
of the 27 epitopes (96%) were positive in at least one of eight subjects tested, and seven of eight subjects (87.5%) responded to at least one epitope. One epitope stimulated
positive responses in six subjects (75%), one epitope stimulated positive responses in ﬁve subjects (62.5%), six epitopes stimulated positive responses in four subjects (50%),
nine  epitopes stimulated positive responses in 3 subjects (37.5%), eight epitopes stimulated positive responses in two subjects (25%), and one epitope stimulated positive
responses in one subject (12.5%).
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Table 3
Individual donors’ responses to the HLA-A2-restricted GAIA Vaccine candidate epitopes.
Table 3a Study subject cohort #1: GAIA Vaccine candidate HLA-A2-restricted epitope ELISpot results (USA)
Peptide ID Sequence H  0863 H 0865 H 0836 H 0833 H 0854 H 0912 H 0843 H 0858 Total
responses
per epitopeA02011
A3001
A02011 A02011;
A2901
A0201;
A0801
A02011;
A3401
A0201 A02011;
A7401
A02011;
A2603
ENV 1001 GIKPVVSTQL – – – – 75 903 – – 2/16
ENV 1002 AVLSIVNRV  – 54 – – – 279 – – 2/16
ENV 1003  RLRDLLLIV – – – – – 389 – – 1/16
ENV  1004 TMGAASITL – 303 – – – 139 – – 2/16
ENV  1005 SLCLFSYHRL – – – – – – – – 0/16
GAG  1012 RMYSPVSIL 46 117 43 – – 199 – – 4/16
GAG 1013 ELKSLYNTV 33 22 – – – – – 129 3/16
GAG 1014 MLKETINEEA – 331 – –  – 106 – – 2/16
NEF 1015  WLEAQEEEEV – – – – – – 25 – 1/16
POL  1006 ALQDSGSEV – – – – – – – – 0/16
POL 1007  KLAGRWPVKV – – – – – – – – 0/16
POL  1008 ELKKIIGQV 33 99 – – 43 76 30 – 5/16
POL  1009 ELAENREIL – 25 – 23 – – – – 2/16
POL  1010 DIQKLVGKL – – 64 – – – – – 1/16
POL  1011 KLVGKLNWA – – – – – 49 – – 1/16
POL  1016 GLKKKKSVTV – – – – – – – – 0/16
TAT 1017 RLEPWKHPG – – – – – 29 – – 1/16
VIF  1018 KISSEVHIPL – 32 – – – 36 – – 2/16
VPR 1019  ETYGDTWTGV – – – – – – – – 0/16
VPU  1020 TMVDMGHLRL – – 33 – – 46 – – 2/16
Total  responses per donor 3/20 8/20 3/20 1/20 2/20 11/20 2/20 1/20
Table  3b Study subject cohort #2: GAIA Vaccine candidate HLA-A2-restricted epitope ELISpot results (USA)
Peptide ID Sequence 0902991  H0014M 0517001 H0023M 0906002 Total
responses
per epitopeA2 A1 A2 A2 A2
A30  A2 A3 A30 A3
B39  B8 B44 B35 B8
Cw16 Cw05 B49 B51
Cw07 Cw04 Cw01
Cw07 Cw07
ENV 1257 NMWQEVGKAM 333 – 72 – – 2/8
GAG 1261 SLYNTVATLY – 290 – 204 121 3/8
POL  1247 HLKTAVQMAV – 230 – – – 1/8
POL  1249 ILKEPVHGVY 2380 – 117 172 – 3/8
VIF  1237 DLADQLIHLY 190 43 – – – 2/8
Total  responses per donor 3/5 3/5 2/5 2/5 1/5
Table 3c Study subject cohort #3: GAIA Vaccine candidate HLA-A2-restricted epitope ELISpot results (Mali)
Peptide ID Sequence 0015267 0015299 0018341 0018349 0018322 0015269 0015404 Total
responses
per epitopeA0231 A0208 A0280 A0208 A0250 A0209 A02
A0285 A0241  A0258 A0231 A0285
A0286  A0208 A0265 A0286
A9206  A0273
A0279
ENV 1001 GIKPVVSTQL – 53 – 37 – – 111 3/8
ENV  1002 AVLSIVNRV 77 49 – – – – 39 3/8
ENV  1004 TMGAASITL 91 – 25 40 – – 102 4/8
ENV  1005 SLCLFSYHRL 61 65 26 34 48 – 74 6/8
ENV  1257 NMWQEVGKAM – – – 40 – – 63 2/8
ENV  3001 QLLLNGSLA – 37 – – 53 – 63 3/8
ENV  3002 WLWYIKIFI – – – – – – 63 1/8
GAG  1012 RMYSPVSIL 64 28 – 54 – – 66 4/8
GAG 1013 ELKSLYNTV 21 – – – – – 83 2/8
GAG  1014 MLKETINEEA 52 49 – – – – 54 3/8
GAG  3003 RTLNAWVKV 28 – – – – – 43 2/8
NEF  3004 LTFGWCFKL – – 80 – – – 88 2/8
POL  1006 ALQDSGSEV 20 – – – 39 22 71 4/8
POL 1008 ELKKIIGQV –  77 – 21 – – 71 3/8
POL  1011 KLVGKLNWA – 27 – – – – 43 2/8
POL  1247 HLKTAVQMAV 103 56 – 33 – – 59 4/8
POL  3005 YQYMDDLYV 39 – – 53 – – 122 3/8
REV  2001 GVGSPQILV 101 – – – 28 – 62 3/8
REV  2002 ILVESPTVL 23 – – – – – 35 2/8
REV 2003 SAEPVPLQL 20 25 – 25 – – 50 4/8
REV  2004 PLQLPPLERL 139 36 – 37 – – 59 4/8
VIF 3006 KVGSLQYLA 35 33 – 36 27 – 63 5/8
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Table 3 (Continued )
Table 3c Study subject cohort #3: GAIA Vaccine candidate HLA-A2-restricted epitope ELISpot results (Mali)
Peptide ID Sequence 0015267  0015299 0018341 0018349 0018322 0015269 0015404 Total
responses
per  epitopeA0231 A0208 A0280 A0208 A0250 A0209 A02
A0285  A0241 A0258 A0231 A0285
A0286  A0208 A0265 A0286
A9206 A0273
A0279
VIF 3007  SLQYLALTA – – 53 45 – – 43 3/8
VIF  3008 SLVKHHMYI 33 – – 40 – – 82 3/8
VIF  1237 DLADQLIHLY – 91 – 41 – – – 2/8
VPR  1019 ETYGDTWTGV – – – – – 47 34 2/8
VPU  3009 KIDRLIDRI – – – – – – – 0/8
Total  responses per donor 16/27 13/27 4/27 14/27 5/27 2/27 25/27
Table 3a Peptide IDs and sequences are shown in columns 1 and 2, respectively. The ID number for each PBMC donor is shown at the top of columns 3–10, and each donor’s
HLA-A alleles are noted directly under the corresponding ID number. Subject IDs in this table have been shortened from those displayed in Table 2a For simplicity, the
table shows only the ELISpot responses that meet a cutoff of at least twice the number of background spots and at least 20 spots per million cells over background. ELISpot
responses that fall below this cutoff point are indicated with a dash mark. Fifteen of the 20 A2 peptides tested with these donors were positive by ELISpot in at least one
subject. Eight donors (H 0911, H 0848, H 0852, H 0845, H 0881, H 0834, H 0856, and H 0840) whose PBMCs did not elicit responses with any of the peptides tested have
been omitted from this table; clinical information for these subjects can be found in Table 2a
Table  3b: Peptide IDs and sequences are shown in columns 1 and 2, respectively. The ID number for each PBMC donor is shown at the top of columns 3–7, and each donor’s
HLA-A alleles are noted directly under the corresponding ID number. PBMCs from these subjects were evaluated for IFN secretion  in response to each of ﬁve A2 peptides
(1237, 1247, 1249, 1257, and 1261). For simplicity, the table shows only the ELISpot responses that meet a cutoff of at least twice the number of background spots and at
least  20 spots per million cells over background. ELISpot responses that fall below this cutoff point are indicated with a dash mark. All ﬁve of the A2 peptides tested with
these donors listed in the table were positive by ELISpot in at least one subject. Three donors (0829001, H0007M, and H0204R) whose PBMCs did not elicit responses with
any  of the peptides tested have been omitted from this table. These subjects were positive for the following HLA alleles: 0829001 (A2, A3, B7, B58, Cw07), H0007M (A2, A29,
B15,  B44, Cw03, Cw16), and H0204R (A2, B40, B57, Cw03, Cw07).
Table  3c Peptide IDs and sequences are shown in columns 1 and 2, respectively. The ID number for each PBMC donor is shown at the top of columns 3–10, and each donor’s
HLA-A alleles are noted directly under the corresponding ID number. For simplicity, the table shows only the ELISpot responses that meet a cutoff of at least twice the number
of  background spots and at least 20 spots per million cells over background. ELISpot responses that fall below this cutoff point are indicated with a dash mark; blank spaces
were left for epitopes that were not tested with a given donor’s PBMCs. Twenty-six of the 27 A2 peptides tested with these donors were positive by ELISpot in at least one
subject. One donor (0015420) whose PBMCs did not elicit responses with any of the peptides tested has been omitted from this table; clinical information for this subject
can be found in Table 2c. Four additional peptides (1007, 1020, 1261, and 1249) were only tested in this subject, but as they did not elicit any ELISpot response, they have
been excluded from this table.
And ﬁnally, eight of the selected HLA-A2 epitopes are still
novel for HIV-1 at the time of submission. The following pep-
tides were conﬁrmed to be immunogenic in IFN ELISpot assays
in PBMC cultures from our HIV-1 infected cohorts: ENV-1001
(GIKPVVSTQL) in both Providence, RI and Bamako, Mali; TAT-
1017 (RLEPWKHPG) and VIF-1018 (KISSEVHIPL) in Providence;
and REV-2001 (GVGSPQILV), REV-2002 (ILVESPTVL), VIF-3006
(KVGSLQYLA), VIF-3007 (SLQYLALTA), and VPU-3009 (KIDRLIDRI)
in Bamako. Epitope VPU-3009 did not elicit any positive IFN
ELISpot responses and has yet to be described as an HIV-1 epitope
in other publications even though it bound to HLA-A2 in vitro; this
may  due to the size of the study cohort or to false positive selection
by our immunoinformatics tools.
4. Discussion
A  globally relevant vaccine for HIV-1 continues to remain elu-
sive due to the dynamic and extraordinary diversity of the virus.
Virus-speciﬁc cytotoxic T-cell responses have been shown to play
a vital role in the control of primary and chronic HIV-1 infec-
tion [16,20,17,72,73], and while T-cell epitopes continuously evolve
under immune pressure, early work showed ﬁtness costs limited
viral escape from CTL [34]. These ﬁndings suggest that a vaccine
capable of raising CTL to the most conserved epitopes would have
the most success at slowing or halting the progression of disease.
This supports our ﬁrm belief that critical highly conserved, high-
afﬁnity epitopes available for vaccine design lie in restricted regions
of the HIV genome that are resistant to selective pressure, where
mutations are slow to evolve and exact a cost on virus replicative
ﬁtness. We  have called these epitopes the “Achilles’ heel” epitopes
of HIV [32]. Due to HIV viral evolution in response to pressure from
HLA-restricted immune responses, many highly immunogenic T-
cell epitopes may  be disappearing from the HIV genome, while
highly  conserved regions of the genome may  also evolve to escape
human immune response [74,75].
In the work presented here, we have employed immunoinfor-
matics methods to search available HIV sequences for both highly
conserved and immunogenic HLA-A2 epitopes. Using this balanced
strategy of selecting for both conservation and immunogenicity,
38 total putative A2 epitopes were chosen and then tested in
assays with PBMCs from HIV-1 infected subjects in two geograph-
ically distinct areas (Providence, Rhode Island, and Bamako, Mali).
This approach to epitope selection is contrasted with alternative
approaches in Fig. 3. By way of comparison, if the peptide selections
had been made to maximize EpiMatrix score but not conserva-
tion, we would have obtained a set of peptides from regions of
the genome that are highly immunogenic but poorly conserved,
covering only 33% of isolates (left bars). If we  had instead selected
peptides maximizing only for conservation, we might have arrived
at a maximally conserved but not very immunogenic set, in this
case 87% coverage of isolates with very low mean EpiMatrix score
of −0.34 (middle bars). Choosing peptides at random would yield
a set that covers approximately 24% of HIV isolates but has very
poor potential immunogenicity (data not shown). Thus, as illus-
trated in Fig. 3, a balanced approach, such as the one used for the
epitopes described here, leads to the selection of epitopes that are
both immunogenic and highly conserved.
The importance of this approach for vaccine design is under-
scored by the re-evaluation of our 2002 selections that was
performed in 2009, at which time we also searched for new, highly
conserved epitopes. The relative conservation of the selected epi-
topes in spite of the dramatic expansion of the number of available
HIV sequences (4-fold over the intervening seven years) suggests
that these selected peptides may  lie in positions of the viral pro-
tein that are essential for functional or structural integrity of the
virus and which would compromise viral ﬁtness. For example,
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Fig. 3. The 38 highest scoring A2-restricted peptides from the HIV sequence were
identiﬁed based on their 2009 EpiMatrix score for binding to HLA-A2, and their
scores  were averaged; on the left side of the graph, the conservation for these pep-
tides was calculated based on the average of the sequences available for analysis
from  GenBank for each peptide in 2009. As shown on the left, though these pep-
tides  are high scoring, their overall conservation is low, indicating that they would
likely not be good candidates for inclusion in an HIV vaccine. This analysis was then
reversed to identify and take the average of the 38 most highly conserved peptides,
and  EpiMatrix scores for these peptides were calculated and averaged, as shown
in the middle of the graph. Despite the high conservation of these peptides, the
low EpiMatrix scores indicate they would be unlikely to be immunogenic, render-
ing  them ineffective in the context of an HIV vaccine. The approach outlined in the
current study combines these two approaches, selecting peptides that are the most
immunogenic and conserved. This approach allows for the identiﬁcation of peptides
that are both immunogenic and conserved, leading to a set of epitopes that would
be  the most useful for inclusion in a pan-HLA-reactive global HIV vaccine.
GAG-3003, located in GAG p2419-27 TLNAWVKVV (TV9), is a well-
deﬁned HLA-A2-restricted epitope located in helix 1 of the capsid
protein and may  be under some functional constraint [57]. Indeed,
going further back than 2002, as shown in Fig. 1, many of our epi-
topes have remained present and conserved in the same proportion
of sequences since the ﬁrst sequence of HIV was  recorded. The
approach utilized in the current study, which limits selections to
those regions that are both conserved and immunogenic, may  have
uncovered the “Achilles’ heel” of the HIV genome. In addition, this
vaccine strategy excludes epitopes that elicit decoy responses to the
vast majority of HLA class I alleles seen during natural infection.
Furthermore, we tested our theory by validating the epitopes
within a population (Providence, Rhode Island, or Bamako, Mali)
and across geographic space (cohorts in both the United States and
Mali). While the number of subjects tested in these two  separate
locations is too small to draw population-based conclusions with
statistical signiﬁcance between ELISpot results and either in vitro
HLA-A2 binding or percent conservation in protein of origin, we
note that the observed responses on two continents point to the
merit of the approach and suggest that the approach may  be used
to identify highly conserved, immunogenic HIV epitopes. Testing
in larger cohorts will be an important aspect of future studies.
Seventy-nine percent (79%) of the 14 peptides tested in both
locations were positive in at least one subject in each region. Given
that the most common subtypes of HIV-1 are clade B in the United
States and clade A in Mali, this remarkable overlap in terms of pep-
tide recognition supports the hypothesis that immunogenicity of
epitopes selected for this study would not be limited by location
and would be important for inclusion in a globally relevant vac-
cine. That hypothesis is supported by the broad analysis shown
in Fig. 2 and by the validation of some of the peptides in other
countries [73,76,78,86,87]. In examining the Providence and Mali
cohorts, there are observable differences in the ELISpot responses.
Some  of these differences may  be related to the different disease
statuses of these groups at the time of enrollment in the study. For
convenience (because few newly infected subjects were being iden-
tiﬁed), subjects in the Providence cohort were selected based on
their willingness to participate and the stability of their HIV infec-
tion (Table 2a and b). In contrast, the subjects in Mali had been
identiﬁed as HIV positive less than one year prior to the start of
the study (Table 2c), though as these donors were recruited from a
clinic that had just recently opened, it is possible that HIV infection
could have been present for longer periods without detection. The
detection of immune response to these epitopes regardless of phase
of disease suggests that epitope conservation between peptide and
patient sequence is more important than stage of disease.
Seventy-ﬁve percent (75%) of the A2 peptides tested in Provi-
dence were positive in at least one subject, and notably, seven of
the eight subjects who  did not respond to these epitopes had been
on long-term antiretroviral therapy (ART). Lower viral loads due to
ART diminishes responses to viral epitopes, and lack of response
in these subjects does not detract from the value of these epitopes
[76,77]. Providence subjects 0865 and 0912 had the most responses
to the A2 epitopes, with eight and eleven responses, respectively.
The broad immune responses of subject 0865 was not surprising, as
this subject was  known to be a long-term non-progressor who had
been infected for over ten years while maintaining low viral load
and normal CD4+ T cell count without the use of ART. This further
validates the importance of broad immune response tied to sur-
vival. And though subject 0912 responded to the most A2 epitopes,
this patient’s viral load and CD4+ T cell counts were more consis-
tent with active disease. Information on ART adherence, resistance,
clinical course, and disease stage for this patient was not available
for this study.
In  general, ELISpot responses to the A2 epitopes in the Mali
subjects were indicative of the broad immune responses seen dur-
ing the early stages of HIV infection (Table 2c). Subjects 15404,
15267, and 18349 demonstrated the broadest immune responses,
responding to more than 50% of the epitopes; these subjects had
relatively low viral loads and normal CD4+ T cells counts, consistent
with early immune control. One study subject responded to more
than 90% of the epitopes tested; although the most recent viral load
was not available for this particular donor during the study time
period, this type of immune response could also be expected in ear-
lier stages of infection. Due to delays in diagnosis, not all subjects
recruited in Mali after their ﬁrst positive HIV test were identiﬁed as
HIV infected at an early stage of disease. The one subject who did
not respond to any of the 31 epitopes tested in ELISpot assays (data
not shown) had a very high viral load (445,000 copies/ml) and low
CD4+ T cell count that would be more typical of chronic, untreated
infection, a condition that also contributes to lack of response, likely
leading to the lack of positive IFN responses in ELISpot assays.
While  95% of the selected epitopes were positive in at least
one subject in either Providence or Mali, no single epitope was
immunodominant within cohorts or across cohorts. This lack of
immunodominance illustrates the importance of including a broad
array of epitopes for the development of a globally relevant vac-
cine [78–80]. There were only three predicted epitopes that did
not elicit a positive response in this set of peptides; two  of these
epitopes (POL-1007 and POL-1016) have been published by other
groups, one as a class II epitope and the other for a different HLA
restriction (Table 1), calling into question the possibility that either
these epitopes were not correctly predicted (by EpiMatrix) or were
not properly processed or presented on HLA-A2. POL-1007 did bind
with very high afﬁnity to HLA-A2 in vitro, which supports its iden-
tiﬁcation as an HLA-A2 epitope. The third epitope for which no
response was  detected is a novel epitope identiﬁed in our 2009
analysis, VPU-3009. The lack of immune response to this epitope
may be a function of its low binding afﬁnity to HLA-A2.
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Epitope-based vaccines containing epitopes restricted by six
“supertype” HLA, such as HLA-A2, are believed to be the best
approach to generate broad T-cell responses with the greatest pos-
sible coverage of the human population [47,48]. In this paper, we
identiﬁed 38 potential HLA-A2 epitopes for inclusion in our GAIA or
other pan-HLA-reactive HIV-1 vaccines, and of these, 36 are good
candidates. In work published previously, our group selected and
conﬁrmed epitopes immunogenic for HLA-B7 [32] and HLA-A3 [48],
and a prior publication by our group describes the validation of
promiscuous “immunogenic consensus sequence” class II epitopes
in Providence and Bamako [49]. In addition to their remarkable con-
servation across years, the utility of the HLA-A2 epitopes described
here is also supported by their aggregate conservation of 48% and
45% across countries and clades, respectively (Fig. 2). While it
appears that HLA-A2 haplotypes are less equipped to ﬁght HIV
due to a low binding afﬁnity for conserved epitopes, Altfeld et al.
have demonstrated that HLA-A2 can contribute to CTL responses in
acutely HIV-1-infected individuals [81]. Furthermore, the fact that
this study identiﬁed immunogenic, highly conserved A2 epitopes
brings hope to the ﬁeld.
Other  groups have made important strides in developing and
evaluating vaccines that are designed to achieve broad coverage
of HIV strains, but these vaccines are derived with a focus only
on highly conserved regions of HIV consensus with the design of
a novel protein, or mosaic protein approach [82–84]. We would
predict that some of the epitopes contained within those regions
would be less immunogenic than the ones described here and bet-
ter quality epitopes could potentially be reverse engineered into the
mosaic sequence. Recently, Perez et al. identiﬁed nine “super-type-
restricted” epitopes recognized in a diverse group of HIV-1-positive
subjects; however, a single-epitope vaccine or an oligo-epitope vac-
cine, such as one based on a handful of epitopes, risks selection of
viral escape variants and might allow re-infection with viral vari-
ants [85,86]. Going forward our strategy will be to continue to use
a balanced approach, identifying vaccine candidate epitopes based
on both high conservation and predicted immunogenicity while
also validating them in vitro in more than one cohort. We  believe
that the insertion of multiple highly conserved T-cell epitopes, as
identiﬁed here, in a single HIV vaccine construct would result in
broader T-cell responses that would improve the breadth of the
immune response [87].
In this study, we have examined a large number of viral genomes
representative of global HIV-1 sequences across an evolutionary
continuum to determine the most highly conserved sequences
across the entire viral proteome. Protective HLA class I alleles
associated with slow virus growth select epitopes that are highly
immunogenic, where escape mutations impart a substantial cost to
replicative ﬁtness. Based upon this principle we have identiﬁed epi-
topes that are highly conserved and likewise have a weak selective
evolutionary advantage. Furthermore, we have validated HLA-A2
class I binding and immunogenicity (i.e., proteasomal processing
and TCR recognition) of these peptides in both acute and chronically
HIV-1-infected individuals.
Since  this was a cross-sectional study of both chronic and early
infected individuals to evaluate immunogenicity, it was  not pos-
sible to determine when these responses arose during the course
of infection or what role they played in control of viral replication.
Studies have shown that CTL responses measured within individ-
uals differ signiﬁcantly between acute and chronic infection, and
early CTL responses are most predictive of disease course [25,88].
It is encouraging that in the Mali cohort of early infected individuals
not receiving ART, four of eight patients controlling virus showed
signiﬁcant breadth of response (13–25 epitopes), while patients
with more chronic infection (Providence) also responded. Thus
chronicity of HIV infection does not preclude immune response to
highly conserved epitopes.
It is well known that epitopes restricted by few HLA class I
alleles confer variable degrees of protection during natural infec-
tion, underscoring the need to design a vaccine that elicits immune
responses that are substantially better than those seen during nat-
ural infection. The identiﬁcation of “Achilles’ heel” epitopes in this
study is an important ﬁrst step. The biggest challenge for HIV vac-
cine design is to identify epitopes restricted by other HLA  class
I and class II alleles and adopt new immunization strategies and
adjuvants that may  lead to an effective way to prime the T-cell
immune responses of these individuals against conserved epitopes
that would impart a substantial ﬁtness cost on the virus and control
or prevent infection.
In  summary, the challenges faced in HIV vaccine design neces-
sitate a balanced approach to epitope identiﬁcation, combining
computational tools with experimental strategies. Our step-by-
step immunoinformatics approach has successfully screened large
amounts of sequence data and deﬁned epitopes that are likely to
accelerate vaccine development. On the other hand, the experi-
mental approach described here does highlight the need to further
validate some of the in silico predictions, as a few of our candi-
dates did not prove to be immunogenic in in vitro assays despite
binding with high afﬁnity to HLA-A2. The approach described here
appears to be an effective means of further triaging sequences to
distil the best vaccine immunogen candidates, particularly in terms
of their conservation over time, which would provide valuable
information and strategies for groups developing multi-epitope,
pan-HLA-reactive vaccines for HIV and other pathogens. In this
paper, we have identiﬁed 38 highly conserved immunogenic T-cell
epitopes. The combination of the remarkable conservation and high
immunogenicity of these epitopes over time and space supports
their potential inclusion in a globally relevant HIV vaccine.
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